Headlands Technologies LLC Purchases Shares of 3,212 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Headlands Technologies LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,212 shares of the biopharmaceutical company’s stock, valued at approximately $81,000.

Several other institutional investors and hedge funds have also made changes to their positions in CLDX. Wellington Management Group LLP raised its stake in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after purchasing an additional 12,213 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after purchasing an additional 6,557 shares during the period. American Century Companies Inc. boosted its position in Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock valued at $15,376,000 after buying an additional 193,093 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Celldex Therapeutics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock valued at $13,755,000 after buying an additional 5,474 shares during the last quarter.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $15.78 on Monday. The company’s fifty day moving average price is $21.18 and its 200 day moving average price is $25.33. The stock has a market capitalization of $1.05 billion, a P/E ratio of -6.14 and a beta of 1.59. Celldex Therapeutics, Inc. has a 1 year low of $15.46 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CLDX shares. Morgan Stanley started coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price objective on the stock. UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.